Analytic reviews: Cellular mechanisms in sepsis

Journal of Intensive Care Medicine

Volumn 22, Issue 2, 2007, Pages 63-72

  Jean Baptiste, Eddy ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cellular; Sepsis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; COMPLEMENT; CYTOKINE; ENDOTOXIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; INTRINSIC FACTOR; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PHOSPHATASE; PROSTACYCLIN; PROSTAGLANDIN; PROTEINASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ACUTE PHASE PROTEIN; AUTACOID;

APOPTOSIS; BACTERIAL MEMBRANE; CELL DAMAGE; CELL DEATH; FUNGUS; GENETIC SUSCEPTIBILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; MICROORGANISM; MORTALITY; MULTIPLE ORGAN FAILURE; NEGATIVE FEEDBACK; NONHUMAN; PATHOGENESIS; POSITIVE FEEDBACK; PRIORITY JOURNAL; REVIEW; SEPSIS; TISSUE INJURY; VIRUS; BIOSYNTHESIS; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACUTE-PHASE PROTEINS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; SEPSIS;

EID: 34047258169     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066606297123     Document Type: Review

References (78)

1. Linde-Zwirble WT, Angus DC, Carcillo J., Lidicker J., Clermont G., Pinsky MR Age-specific incidence and outcome of sepsis in the US: analysis of incidence, outcome, and associated cost of care. Crit Care Med. 1999 ; 27 (suppl 1). A33.
2. Albert C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med. 2002 ; 28: 108-121.
3. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA. 1997 ; 278: 234-240.
4. Shapiro L., Gelfand JA Cytokines and sepsis: pathology and therapy. New Horiz. 1993 ; 1: 13-22.
5. Corriveau CC, Danner RL Endotoxin as a therapeutic target in septic shock. Infect Agents Dis. 1993 ; 2: 35-40.
6. Takeuchi O., Hoshino K., Kawai T., et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacteria cell wall components. Immunity. 1999 ; 11: 443-451.
7. Peters CJ, Zaki S. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med. 2002 ; 30 (suppl): S268 - S273.
8. Crislip MA, Edwards JE Jr. Candidiasis. Infect Dis Clin North Am. 1989 ; 3: 103-110.
9. Manthous CA, Hall JB, Samsel RW Endotoxin in human disease. Part 1: biochemistry, assay, and possible role in diverse states. Chest. 1993 ; 104: 1572-1581.
10. Young LS, Gascon R., Alam S., et al. Monoclonal antibodies for treatment of gram-negative infections. Rev Infect Dis. 1989 ; 11 (suppl 7). S1564 - S1571.
11. Teng NN, Kaplan HS, Herbert JM, et al. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci U S A. 1985 ; 82: 1790-1794.
12. Wang H., Vishnubhakat JM, Bloom O., et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1β) stimulate release of high mobility group protein-1 by pituicytes. Surgery. 1999 ; 126: 389-392.
13. Wright SD CD14 and innate recognition of bacteria. J Immumol. 1995 ; 155: 6-8.
14. Lien E., Ingalls RR Toll-like receptors. Crit Care Med. 2002 ; 30 (suppl 1). S1 - S11.
15. Visintin A., Mazzoni A., Spitzer JA, et al. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to toll-like receptor 4. Proc Natl Acad Sci U S A. 2001 ; 98: 12156-12161.
16. Arbabi S., Maier RV Mitogen-activated protein kinases. Crit Care Med. 2002 ; 30 (suppl 1). S74 - S79.
17. Tanowitz HB, Chan J. Gram-positive sepsis. Crit Care Med. 2000 ; 28: 3081-3082.
18. Sriskandandan S., Cohen J. Gram-positive sepsis mechanisms and differences from gram-negative sepsis. Infect Dis Clin North Am. 1999 ; 13: 392-412.
19. Tyler UL, Fields BN Introduction to virus and viral diseases: In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4 th ed. New York, NY: John Wiley & Sons ; 1995.
20. Hadley S., Lee WW, Ruthazer R., Nasraway SA Candidemia as a cause of sepsis shock and multiple organ failure in immunocompromised patients. Crit Care Med. 2002 ; 30: 1808-1814.
21. Williams G., Giroir BP Regulation of cytokine gene expression: tumor necrosis factor, interleukin-1, and emerging biology of cytokine receptors. New Horiz. 1995 ; 3: 276-287.
22. Murphy K., Haudek SB, Thompson M., Giroir BP Molecular biology of septic shock. New Horiz. 1998 ; 6: 181-193.
23. Mahidara R., Billiar TR Apoptosis in sepsis. Crit Care Med. 2000 ; 28 (suppl): 105-113.
24. Kumar A., Thota V., Dee L., et al. Tumor necrosis factor-α and interleukin-1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996 ; 183: 949-958.
25. Parker MM, Shelhamer JH, Natanson C., et al. Serial cardiovascular variables in survivors and non-survivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med. 1987 ; 15: 923-929.
26. Gauldie J., Richards C., Harnish D., et al. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987 ; 84: 7251-7255.
27. Oberholzer A., Oberholzer C., Moldaver LL Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med. 2000 ; 28 (suppl): N3 - N12.
28. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999 ; 285: 248-251.
29. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., et al. Persistent elevation of high mobility group box-1 protein (HMGB-1) in patients with severe sepsis and septic shock. Crit Care Med. 2005 ; 33: 564-573.
30. Calandra T., Bernhagen J., Mitchell RA, et al. The macrophage is an important and previously unrecognized source of macrophage migratory inhibitory factor. J Exp Med. 1994 ; 179: 1895-1992.
31. Calandra T., Echtenacher B., Le Roy D., et al. Protection from septic shock by neutralization of macrophage migratory inhibitory factor. Nat Med. 2000 ; 6: 164-169.
32. Leng L., Bucala R. Macrophage migration inhibitory factor. Crit Care Med. 2005 ; 33 (suppl): S475 - S477.
33. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz. 1995 ; 3: 1-32.
34. Brady Ajb, Pode-Wilson PA, Harding SE, et al. Nitric oxide production with cardiac myocytes reduces their contractility in endoxemia. Am J Physiol. 1992 ; 263: H1963 - H1966.
35. Dries DJ Activation of the clotting system and complement after trauma. New Horiz. 1996 ; 4: 276-288.
36. Bulger EM, Maier RV Lipid mediators in the pathophysiology of critical illness. Crit Care Med. 2000 ; 28 (suppl): N27 - N36.
37. Oettinger W., Berger D., Berger HG The clinical significance of prostaglandins and thromboxane as mediators of septic shock. Klin Wochenschr. 1987 ; 65: 61-68.
38. Campbell WB, Halushka PV Lipid-derived autocoids. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's Pharmacological Basis of Therapeutics. 9 th ed. New York, NY: McGraw-Hill ; 1996: 601-616.
39. Zimmernan GA, Elstad MR, Lorant DE, et al. Platelet-activating factor: new roles in cell-cell interactions. J Lipid Mediat Cell Signal. 1994 ; 10: S7 - S59.
40. Ayala A., Chaudry IH Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz. 1996 ; 4: 265-275.
41. Pannen Bhj, Robothan JL The acute-phase response. New Horiz. 1995 ; 3: 183-197.
42. Steel DM, Whitehead AS The major acute phase reactants: C-reactive protein, serum amyloid P component, and serum amyloid A protein. Immunol Today. 1994 ; 15: 81-88.
43. Hartman DL, Bernard GR, Helterbrand JD, Fisher CJ Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis [abstract]. Intensive Care Med. 1998 ; 24 (suppl 1). S77.
44. Joyce DE, Gelbert L., Ciaccia A., et al. Gene expression profile of antithrombic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001 ; 276: 11199-11203.
45. Fisher CJ, Yan SB Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. 2000 ; 28: S49 - S56.
46. Scumpia PO, Moldawer LL Biology of interleukin-10 and its regulatory roles in sepsis. Crit Care Med. 2005 ; 33 (suppl): S468 - S471.
47. Oberholzer C., Oberholzer A., Bahjat FR, et al. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Natl Acad Sci U S A. 2001 ; 98: 11503-11508.
48. Oberholzer A., Oberholzer C., Bahjat FR, et al. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dentritic cells. J Immunol. 2002 ; 168: 3412-3418.
49. van Zee KS, Kohno T., Fischer E., et al. Tumor necrosis soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 ; 89: 4845-4849.
50. Olsen NJ, Stein CM New drugs for rheumatoid arthritis. N Engl J Med. 2004 ; 350: 2167-2179.
51. Christians ES, Yan LJ, Benjamin IJ Heat shock factor 1 and heat shock proteins: critical partners in protection against acute cell injury. Crit Care Med. 2002 ; 30 (suppl): S43 - S50.
52. Shanley TP Phosphatases: counterregulatory role in inflammatory cell signaling. Crit Care Med. 2002 ; 30 (suppl): S80 - S88.
53. Ray A., Prefontaine KE Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994 ; 91: 752-756.
54. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994 ; 63: 451-486.
55. Radonski MW, Balmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A. 1990 ; 87: 10043-10047.
56. Fourrier F., Bricard H., Cohen Y. Corticotherapie au cours du choc septique et du syndrome de detresse respiratoire de l'adulte. Réanim Urg. 2000 ; 9: 597-603.
57. Annane D., Sebille V., Troche G., et al. A 3-level prognostic classification in septic shock based on prognostic levels and cortisol response to corticotropin. JAMA. 2000 ; 283: 1038-1045.
58. Brinkman BM, Huizinga Twj, Kurban SS, et al. Tumor necrosis factor-α gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? Br J Rheumatol. 1997 ; 36: 516-521.
59. Arnett FC Rheumatoid arthritis. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21 st ed. Philadelphia, Pa: W. B. Saunders Co ; 2000: 1492-1499.
60. Mira JP, Cariou A., Grall F., et al. Association TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA. 1999 ; 282: 561-568.
61. Appoloni O., Dupont E., Vandercruys M., et al. Association of tumor necrosis factor 2 allele with plasma tumor necrosis factor alpha levels and mortality from sepsis shock. Am J Med. 2001 ; 110: 486-488.
62. Waterer GW, Quasney MW, Cantor RM, et al. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med. 2001 ; 163: 1599-1604.
63. Reid CL, Perrey C., Pravica V., et al. Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med. 2002 ; 30: 2216-2221.
64. Pociot F., Briant L., Jongenneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles wit the secretion of TNFα and TNFβ by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993 ; 23: 224-231.
65. Stuber F., Udalova IA, Book M., et al. - 308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to liposaccharide inducibility of the human TNF promoter. J Inflamm. 1996 ; 46: 42-50.
66. Derkx Bhf, Bruin KF, Jongenneel CV, et al. Familial differences in endotoxin-induced TNF release in whole blood and peripheral blood mononuclear cells in vitro; relationship to HLA-haptotype and TNF gene polymorphism. In: Bruin KF, ed. Endotoxin Responsiveness in Humans. Amsterdam, the Netherlands: Thesis ; 1994: 51-64.
67. Fang XM, Schroder S., Hoeft A., et al. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med. 1999 ; 27: 1330-1334.
68. Lowe PR, Galley HF, Abdel-Fattah A., et al. Influence of interleukin-10 expression and survival in critically ill patients. Crit Care Med. 2003 ; 31: 34-38.
69. Gallagher PM, Lowe G., Fitzgerald T., et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax. 2003 ; 58: 154-156.
70. Texereau J., Pene F., Chiche JD, et al. Importance of hemostatic gene polymorphisms for susceptible to and outcome of severe sepsis. Crit Care Med. 2004 ; 32 (suppl): S313 - S319.
71. Mesters RM, Florke N., Ostermann H., et al. Increase of plasminogen activator inhibitor levels predicts outcome of patients with sepsis. Thromb Haemost. 1996 ; 75: 902-907.
72. Westendorp RG, Hottenga JJ, Slaboom PE Variation in plasminogen activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet. 1999 ; 354: 561-563.
73. Hermans PW, Hibberd ML, Booy R., et al. 4G/5G promotor polymorphism in the plasminogen activator-inhibitor 1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet. 1999 ; 354: 555-560.
74. Menges T., Hermans PW, Little SG, et al. Plasminogen activator-inhibitor- 1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet. 2001 ; 357: 1096-1097.
75. Ruokonen E., Takala J., Kari A., Alhava E. Septic shock and multiple organ failure. Crit Care Med. 1991 ; 19: 1146-1151.
76. Livingston DH, Mosenthal AC, Deitch EA Sepsis and multiple organ dysfunction syndrome: a clinical-mechanistic overview. New Horiz. 1995 ; 3: 257-266.
77. Goris Rja, te Boekhorst Tpa, Nuytinck Jks, et al. Multiple organ failure: generalized autodestructive inflammatory. Arch Surg. 1985 ; 120: 1109-1115.
78. Garrison RN, Fry DE, Berborich S., et al. Enterococcal bacteremia: clinical implications and determinants of death. Ann Surg. 1982 ; 196: 43-47.